本文選題：急性髓系白血病 + miR-550-1　； 參考：《浙江大學(xué)》2016年博士論文

【摘要】：第一部分急性髓系白血病中新的抑癌性microRNA——miR-550-1的發(fā)現(xiàn),分析其在AML患者中的表達(dá)水平,并探討其上游調(diào)控機(jī)制目的：篩選出急性髓系白血病(AML)中新的抑癌性microRNAs (miRNAs),并分析其表達(dá)情況。方法：1.Exiqon miRCURY LNA arrays分析85例AML患者與15例正常對(duì)照標(biāo)本間差異表達(dá)的miRNAs; 2.TaqMan qPCR鑒定AML患者中特定miRNA的表達(dá)水平,驗(yàn)證芯片結(jié)果；3.分析TCGA數(shù)據(jù)庫(kù)中194例AM,患者miR-550-1啟動(dòng)子區(qū)CpG島甲基化程度,并利用miR-22的啟動(dòng)子區(qū)CpG島甲基化程度作陰性對(duì)照；4.利用0、0.5、1、2、4μM不同濃度去甲基化藥物地西他濱處理AML細(xì)胞株96h,觀察處理后miR-550-1表達(dá)量改變的情況。結(jié)果：1. Exiqon miRCURY LNA arrays芯片篩選出了12個(gè)在AML患者中低表達(dá)而在正常對(duì)照中高表達(dá)的miRNAs,分別為：miR-150、miR-148a、miR-29a、miR-29b、 miR-184、miR-22、miR-342-3p、miR-423-5p、miR-550-1、miR-660、miR-768-3p、 miR-768-5p (P值均小于0.0001,假發(fā)現(xiàn)率(false discovery rate, FDR)均小于0.0001)；2.從篩選的結(jié)果中我們挑選了miR-550-1作為研究對(duì)象,通過(guò)TaqmanqPCR檢測(cè)發(fā)現(xiàn)AML患者中miR-550-1的表達(dá)量較正常對(duì)照確實(shí)是顯著下調(diào)的(P=0.003)；3.通過(guò)分析TCGA數(shù)據(jù)庫(kù),我們發(fā)現(xiàn)194例AML患者miR-550-1啟動(dòng)子區(qū)CpG島較miR-22啟動(dòng)子區(qū)CpG島的甲基化程度明顯升高；4.用0、0.5、1、2、4μM不同濃度地西他濱處理Kasumi-1和MV4-11細(xì)胞96h后,可誘導(dǎo)細(xì)胞內(nèi)miR-550-1表達(dá)上調(diào),相對(duì)表達(dá)水平分別為Kasumi-1 (1、1.19、1.18、1.14、1.29), MV4-11 (1、3.30、7.33、20.15、13.96).結(jié)論：1.與正常對(duì)照標(biāo)本相比,AML患者中miR-550-1表達(dá)量顯著降低；2.miR-550-1啟動(dòng)子區(qū)CpG島處于高度甲基化狀態(tài)；3.利用去甲基化藥物地西他濱可以促進(jìn)AML細(xì)胞株中miR-550-1的表達(dá)。第二部分觀察miR-550-1對(duì)急性髓系白血病細(xì)胞活性、增殖、凋亡、周期、克隆形成能力以及小鼠急性髓系白血病骨髓移植模型發(fā)生發(fā)展的影響目的：探索外源性過(guò)表達(dá)miR-550-1后對(duì)AML細(xì)胞株及小鼠髓系祖細(xì)胞生物學(xué)功能的影響。方法：1.構(gòu)建miR-550-1逆轉(zhuǎn)錄病毒過(guò)表達(dá)載體,PCR定點(diǎn)突變方法構(gòu)建miR-550-1種子序列突變的變異體miR-550-1逆轉(zhuǎn)錄病毒載體；2.利用逆轉(zhuǎn)錄病毒感染AML細(xì)胞株和小鼠髓系祖細(xì)胞,構(gòu)建miR-550-1穩(wěn)定過(guò)表達(dá)細(xì)胞株,其中小鼠髓系祖細(xì)胞還需共轉(zhuǎn)染MLL-AF9或AE9a融合基因,利用TaqMan qPCR驗(yàn)證過(guò)表達(dá)miR-550-1是否成功；3.通過(guò)MTT、臺(tái)盼藍(lán)染色細(xì)胞計(jì)數(shù)檢測(cè)AML細(xì)胞活性和細(xì)胞增殖；4.流式細(xì)胞術(shù)檢測(cè)AML細(xì)胞株的細(xì)胞周期和細(xì)胞凋亡；5.Western blot方法檢測(cè)細(xì)胞增殖、周期、凋亡相關(guān)信號(hào)通路蛋白的變化；6.Dot blot方法檢測(cè)細(xì)胞內(nèi)m6A表達(dá)水平變化；7.小鼠髓系祖細(xì)胞集落培養(yǎng)檢測(cè)細(xì)胞克隆形成能力；8.Wright-Giemsa染色檢測(cè)細(xì)胞形態(tài)及分化情況；9.小鼠骨髓移植模型檢測(cè)miR-550-1對(duì)一代、二代移植小鼠AML疾病發(fā)生發(fā)展的影響。結(jié)果：1.逆轉(zhuǎn)錄病毒感染細(xì)胞后可顯著升高Kasumi-1、MV4-11、小鼠髓系祖細(xì)胞內(nèi)miR-550-1的表達(dá)水平(P0.001)；2.在Kasumi-1、MV4-11、小鼠髓系祖細(xì)胞中miR-550-1過(guò)表達(dá)后可以明顯抑制細(xì)胞活性和細(xì)胞增殖能力；3Kasum i-1細(xì)胞過(guò)表達(dá)miR-550-1,72h后G0/G1細(xì)胞比例增加10.4%,96h凋亡細(xì)胞比例增加7.76%,PARP蛋白激活,p-AKT和CDK6蛋白表達(dá)被抑制,m6A表達(dá)水平被抑制；4.共感染miR-550-1和MLL-AF9、AE9a融合基因的小鼠髓系祖細(xì)胞較單獨(dú)轉(zhuǎn)染融合基因的細(xì)胞每一代的克隆形成數(shù)要少(P0.05),克隆中細(xì)胞總量也顯著降低(P0.05),分化成熟的細(xì)胞逐代增加；5.在小鼠骨髓移植中,與對(duì)照組相比較,miR-550-1過(guò)表達(dá)組小鼠一代移植(中位生存時(shí)間分別為77.5天和105天)和二代移植(中位生存時(shí)間分別為27天和33天)的總體生存時(shí)間均顯著延長(zhǎng)(P值分別為0.035和0.010)。結(jié)論：1.過(guò)表達(dá)miR-550-1后可抑制AML細(xì)胞生長(zhǎng),降低細(xì)胞活性,促進(jìn)細(xì)胞凋亡,誘導(dǎo)細(xì)胞發(fā)生G0/G1期阻滯,抑制RNA上m6A表達(dá)；2.過(guò)表達(dá)miR-550-1后可抑制共感染MLL-AF9或AE9a融合基因的小鼠髓系祖細(xì)胞每代克隆形成能力,并誘導(dǎo)細(xì)胞分化；3.過(guò)表達(dá)miR-550-1可抑制小鼠骨髓移植模型AML的發(fā)生發(fā)展,延長(zhǎng)小鼠總體生存時(shí)間,降低惡性原始細(xì)胞比例,促進(jìn)小鼠細(xì)胞分化,減輕小鼠腫瘤負(fù)荷。第三部分探索miR-550-1的靶基因和影響急性髓系白血病發(fā)生發(fā)展的分子機(jī)制目的：探索miR-550-1在體內(nèi)體外影響急性髓系白血病發(fā)生發(fā)展的分子機(jī)制,即通過(guò)調(diào)控哪些潛在靶基因而實(shí)現(xiàn)其生物學(xué)功能,并通過(guò)rescue實(shí)驗(yàn)驗(yàn)證靶基因功能。方法：1.結(jié)合在線數(shù)據(jù)庫(kù)預(yù)測(cè)miR-550-1的潛在靶基因；2.通過(guò)TCGA、CALGB和已檢測(cè)mRNA表達(dá)譜芯片結(jié)果確定miR-550-1潛在靶基因,并分析在AML患者中各靶基因的表達(dá)量與miR-550-1表達(dá)水平間的相關(guān)性；3.構(gòu)建潛在靶基因3'UTR的luciferase熒光雙報(bào)告載體,對(duì)靶基因與miR-550-1的結(jié)合序列進(jìn)行鑒定；4.利用qPCR、Western blot方法對(duì)miR-550-1過(guò)表達(dá)細(xì)胞株中靶基因在RNA和蛋白質(zhì)水平上的表達(dá)情況進(jìn)行驗(yàn)證；5.克隆與miR-550-1表達(dá)負(fù)性相關(guān)靶基因的CDS區(qū),構(gòu)建其慢病毒過(guò)表達(dá)載體；6.利用靶基因的慢病毒載體在miR-550-1過(guò)表達(dá)細(xì)胞株中進(jìn)行rescue實(shí)驗(yàn)；7.通過(guò)IPA軟件分析靶基因間的相互聯(lián)系,以及對(duì)下游信號(hào)通路的影響。結(jié)果：1.結(jié)合生物信息學(xué)網(wǎng)站靶基因預(yù)測(cè)結(jié)果、TCGA和CALGB數(shù)據(jù)庫(kù)以及前期mRNA表達(dá)譜芯片結(jié)果,識(shí)別miR-550-1的四個(gè)潛在下游靶基因,分別為WWTR1、FZD5、SOX 11、PAX8;2.雙熒光素酶報(bào)告實(shí)驗(yàn)發(fā)現(xiàn)較對(duì)照或突變序列而言,只有含WWTR1、FZD5、SOX11、PAX8正常3'UTR序列的質(zhì)粒與miR-550-1共轉(zhuǎn)后可降低熒光比值(P均0.05),通過(guò)Western blot. qPCR結(jié)果發(fā)現(xiàn),過(guò)表達(dá)miR-550-1后可以降低VWTR1、FZD5、SOX11、PAX8的蛋白水平和mRNA水平；3.在過(guò)表達(dá)miR-550-1的Kasumi-1穩(wěn)定細(xì)胞株中,過(guò)表達(dá)WWTR1靶基因后G0/G1期細(xì)胞比例較未過(guò)表達(dá)WWTR1組減少了9.1%,細(xì)胞活性增加,生長(zhǎng)增快；4.IPA軟件分析顯示miR-550-1對(duì)下游Wnt信號(hào)通路的影響最為明顯。結(jié)論：1. WWTR1、FZD5、SOX11、PAX8均為miR-550-1下游靶基因；2.miR-550-1通過(guò)抑制WWTR1、FZD5、SOX11、PAX8,可調(diào)控AML細(xì)胞株中Wnt信號(hào)通路的活性；3.過(guò)表達(dá)靶基因WWTR1可以部分逆轉(zhuǎn)miR-550-1對(duì)AML細(xì)胞株生長(zhǎng)抑制、周期阻滯的作用。
[Abstract]:The first part of the acute myeloid leukemia, the discovery of a new tumor suppressor microRNA - miR-550-1, analyzed its expression in AML patients and explored the aim of its upstream regulatory mechanism: to screen out the new tumor suppressor microRNAs (miRNAs) in acute myeloid leukemia (AML) and to analyze its expression. Methods: 1.Exiqon miRCURY LNA arrays points. The differential expression of miRNAs between 85 AML patients and 15 normal controls was analyzed; 2.TaqMan qPCR was used to identify the expression level of specific miRNA in AML patients and to verify the results of the chip; 3. analysis of the 194 AM in the TCGA database, the degree of CpG Isle methylation in the miR-550-1 promoter region of the patients and the negative control of the CpG island methylation degree in the miR-22 promoter region. 4. the AML cell line 96h was treated with 0,0.5,1,2,4 mu M with different concentration of demethylation drugs, and the changes of miR-550-1 expression after treatment were observed. Results: 1. Exiqon miRCURY LNA arrays chips were used to screen 12 low expressions in AML patients and high expression in normal controls. -29b, miR-184, miR-22, miR-342-3p, miR-423-5p, miR-550-1, miR-660, miR-768-3p, miR-768-5p (P values are less than 0.0001, false discovery rate is less than 0.0001). 2. from the screening results we selected as the research pair of images. The control was significantly down-regulated (P=0.003); 3. by analyzing the TCGA database, we found that the degree of methylation of CpG island in the miR-550-1 promoter region of the AML patients was significantly higher than that of CpG island in the miR-22 promoter region; 4. with 0,0.5,1,2,4 u M and different concentrations of the Kasumi-1 and MV4-11 cell 96h, the expression of the intracellular expression could be induced. The relative expression level was Kasumi-1 (1,1.19,1.18,1.14,1.29) and MV4-11 (1,3.30,7.33,20.15,13.96). Conclusion: 1. compared with normal control specimens, miR-550-1 expression in AML patients decreased significantly; CpG island in 2.miR-550-1 promoter region was in high methylation state; 3. using demethylation drug, citripara could promote AML fine. The second part observed the effect of miR-550-1 on the activity, proliferation, apoptosis, cycle, clone formation, and development of acute myeloid leukemia bone marrow transplantation model in acute myeloid leukemia: To explore the biological work of AML cell lines and medullary progenitor cells after miR-550-1 overexpression of miR-550-1 Methods: 1. construction of miR-550-1 retrovirus overexpression vector, PCR fixed-point mutation method to construct variant miR-550-1 retrovirus vector of miR-550-1 seed sequence; 2. using retrovirus infected AML cell line and mouse medullary progenitor cells to construct a miR-550-1 stable overexpressed cell line, in which the medullary lineage of mice is fine. MLL-AF9 or AE9a fusion gene was co transfected, and TaqMan qPCR was used to verify the success of miR-550-1 over expression of miR-550-1; 3. through MTT, trypan blue staining cells were used to detect AML cell activity and cell proliferation, and 4. flow cytometry was used to detect the cell cycle and apoptosis of AML cell lines, and 5.Western blot method was used to detect cell proliferation, cycle and apoptosis. The change of related signaling pathway protein; 6.Dot blot method to detect the change of m6A expression in cell; 7. mouse myeloid progenitor cell culture to detect cell clone formation ability; 8.Wright-Giemsa staining to detect cell morphology and differentiation; 9. mouse bone marrow transplantation model was used to detect miR-550-1 to the first generation, and the two generation transplanted mice AML disease hair. Results: the expression level of miR-550-1 in Kasumi-1, MV4-11, mouse medullary progenitor cells (P0.001) was significantly increased after 1. retroviral infection cells, and 2. in Kasumi-1, MV4-11, mouse myeloid progenitor cells could obviously inhibit cell viability and cell proliferation ability; 3Kasum I-1 cells overexpressed miR-. After 550-1,72h, the proportion of G0/G1 cells increased by 10.4%, the proportion of 96h apoptotic cells increased by 7.76%, PARP protein was activated, the expression of p-AKT and CDK6 protein was inhibited, and the expression level of m6A was suppressed; 4. co infected mouse medullary progenitors of miR-550-1 and AE9a gene were less than those of each generation of cells transfected with the fusion gene alone (P0.05). The total number of cells in the clones decreased significantly (P0.05) and the differentiated mature cells increased by generation. 5. in mice bone marrow transplantation, the total survival time of the miR-550-1 overexpressed group (median survival time of 77.5 and 105 days respectively) and the two generation (27 days and 33 days respectively) in the mice was compared with the control group. Lengthening (P values are 0.035 and 0.010 respectively). Conclusion: 1. overexpression of miR-550-1 can inhibit the growth of AML cells, reduce cell activity, promote cell apoptosis, induce G0/G1 arrest and inhibit m6A expression on RNA, and 2. overexpression of miR-550-1 can inhibit the formation of each generation of mouse progenitor cells co infected with MLL-AF9 or AE9a fusion genes. 3. overexpression of miR-550-1 could inhibit the occurrence and development of mouse bone marrow transplantation model AML, prolong the total survival time of mice, reduce the proportion of malignant primitive cells, promote the differentiation of mouse cells and reduce the load of tumor in mice. The third part explores the target gene of miR-550-1 and affects the development of acute myeloid leukemia. Molecular mechanism Objective: To explore the molecular mechanism of miR-550-1 in the development of acute myeloid leukemia in vitro and in vivo, namely, to realize its biological function by regulating which potential target genes to realize its biological function, and to verify the target gene function through rescue experiment. Method: 1. the potential target gene of miR-550-1 is predicted by online database; 2. through TCGA, CALGB The potential target gene of miR-550-1 was determined with the results of the detected mRNA expression chip, and the correlation between the expression of target genes and the level of miR-550-1 expression in AML patients was analyzed. 3. the luciferase fluorescent double reporting vector of the potential target gene 3'UTR was constructed, and the binding sequence of the target gene and miR-550-1 was identified, and 4. using qPCR, Western blo. T was used to verify the expression of target gene at the level of RNA and protein in miR-550-1 overexpressed cell lines; 5. clone and miR-550-1 expressed the CDS region of the negative related target gene, construct its lentivirus overexpression vector, and 6. use the lentivirus vector of the target gene to carry out rescue experiment in the miR-550-1 over the cell line, and 7. through IPA. The software analyses the interconnections between the target genes and the influence on the downstream signal pathways. Results: 1. the results of the target gene prediction of the bioinformatics website, the TCGA and CALGB database and the earlier mRNA expression chip results identify the four potential downstream target genes of miR-550-1, including WWTR1, FZD5, SOX 11, PAX8; 2. double Luciferase Report. It was found that only WWTR1, FZD5, SOX11, PAX8 normal 3'UTR sequences could reduce the ratio of fluorescence (P 0.05), and the results of Western blot. qPCR showed that the protein level and the level of PAX8 were reduced by Western blot. qPCR. In the Kasumi-1 stable cell line, after overexpressing WWTR1 target gene, the proportion of G0/G1 phase cells decreased by 9.1%, cell activity increased and growth increased faster than that of the unoverexpressed WWTR1 group; 4.IPA software analysis showed that miR-550-1 had the most obvious influence on the downstream Wnt signaling pathway. Conclusion: 1. WWTR1, FZD5, SOX11, PAX8 are the downstream target genes of miR-550-1. 0-1 by inhibiting WWTR1, FZD5, SOX11 and PAX8, the activity of Wnt signaling pathway in AML cell lines can be regulated, and 3. over expression of target gene WWTR1 can partly reverse the effect of miR-550-1 on the growth inhibition and periodic block of AML cell lines.
【學(xué)位授予單位】：浙江大學(xué)
【學(xué)位級(jí)別】：博士
【學(xué)位授予年份】：2016
【分類(lèi)號(hào)】：R733.71

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 王前;骨髓增生異常綜合征轉(zhuǎn)化為急性髓系白血病1例[J];白血病.淋巴瘤;2001年06期

2 溫莉娟,孟昭彥,劉利明,侯美仙,陳麗燕;染色體t(8;21)伴急性髓系白血病六例[J];中華醫(yī)學(xué)遺傳學(xué)雜志;2004年04期

3 徐升,李麗,朱子玲,張日;血管內(nèi)皮生長(zhǎng)因子在急性髓系白血病中的表達(dá)[J];中國(guó)血液流變學(xué)雜志;2004年03期

4 上海市中美白血病合作課題組;微分化急性髓系白血病四例報(bào)告[J];中華血液學(xué)雜志;2005年06期

5 夏云金,萬(wàn)楚成,郭仁慈;不同病期急性髓系白血病患者紅細(xì)胞免疫功能檢測(cè)及臨床意義[J];微循環(huán)學(xué)雜志;2005年02期

6 李玉芹;戴瓊;龔武清;楊曉秋;;微分化急性髓系白血病1例[J];淮海醫(yī)藥;2007年04期

7 劉凱奇;秘營(yíng)昌;李大鵬;白潔;井麗萍;卞壽庚;王建祥;;急性髓系白血病合并慢性淋巴細(xì)胞白血病一例報(bào)道及文獻(xiàn)復(fù)習(xí)[J];繼續(xù)醫(yī)學(xué)教育;2007年04期

8 謝曉恬;;兒童急性髓系白血病的診斷與治療[J];實(shí)用兒科臨床雜志;2011年15期

9 ;探尋白血病線索[J];世界科學(xué);2013年08期

10 肖志堅(jiān)，王建祥，郝玉書(shū)，李建波，陳佩貞，卞壽庚，，錢(qián)林生，孟慶祥;兩例無(wú)t（8；21）M_（2b）型急性髓系白血病的基因檢測(cè)[J];中華醫(yī)學(xué)遺傳學(xué)雜志;1994年05期

相關(guān)會(huì)議論文 前10條

1 李達(dá);葛志紅;吳順杰;梁冰;;白血康為主治療難治性復(fù)發(fā)急性髓系白血病12例臨床分析[A];第六屆全國(guó)中西醫(yī)結(jié)合血液病學(xué)術(shù)會(huì)議論文匯編[C];2002年

2 范洵楠;邵曉雁;楊永公;陳兵;許景艷;孫雪梅;歐陽(yáng)建;;預(yù)激療法治療難治性或復(fù)發(fā)性急性髓系白血病的療效分析[A];2005年華東六省一市血液病學(xué)學(xué)術(shù)會(huì)議暨浙江省血液病學(xué)學(xué)術(shù)年會(huì)論文匯編[C];2005年

3 華佳葉;龐纓;蔡曉東;葉絮;馮瑩;;急性髓系白血病自體造血干細(xì)胞移植后的維持化療[A];第11次中國(guó)實(shí)驗(yàn)血液學(xué)會(huì)議論文匯編[C];2007年

4 王建祥;;急性髓系白血病的合理治療[A];2011年浙江省血液病學(xué)術(shù)年會(huì)暨浙江省醫(yī)學(xué)會(huì)血液病學(xué)分會(huì)成立50周年慶典論文匯編[C];2011年

5 楊文華;;急性髓系白血病中西醫(yī)結(jié)合治療策略[A];2009年浙江省中醫(yī)藥學(xué)會(huì)血液病學(xué)術(shù)年會(huì)、浙江省中西醫(yī)結(jié)合學(xué)會(huì)血液病學(xué)術(shù)年會(huì)暨國(guó)家級(jí)中西醫(yī)結(jié)合血液病新進(jìn)展繼續(xù)教育學(xué)習(xí)班論文匯編[C];2009年

6 顧龍君;帖利軍;陳靜;潘慈;董璐;陳靜;葉輝;薛惠良;湯靜燕;王耀平;鄒佳音;;兒童急性髓系白血病預(yù)后因素分析[A];中華醫(yī)學(xué)會(huì)第八次全國(guó)血液學(xué)學(xué)術(shù)會(huì)議論文匯編[C];2004年

7 張曉燕;李軍民;;急性髓系白血病染色體異常與療效關(guān)系[A];中華醫(yī)學(xué)會(huì)第八次全國(guó)血液學(xué)學(xué)術(shù)會(huì)議論文匯編[C];2004年

8 陳賽娟;王月英;王蘭;周光飚;梁洋;焦波;武傳鳳;陳竺;;T(8；21)急性髓系白血病多步驟發(fā)病機(jī)制和靶向治療研究[A];第11次中國(guó)實(shí)驗(yàn)血液學(xué)會(huì)議論文匯編[C];2007年

9 金潔;;急性髓系白血病的治療進(jìn)展[A];2007年浙江省血液病學(xué)術(shù)年會(huì)論文匯編[C];2007年

10 金潔;;急性髓系白血病的治療進(jìn)展[A];第七屆全國(guó)血液免疫學(xué)學(xué)術(shù)大會(huì)暨2008年浙江省血液病學(xué)術(shù)年會(huì)論文匯編[C];2008年

相關(guān)重要報(bào)紙文章 前3條

1 中國(guó)醫(yī)學(xué)科學(xué)院血液學(xué)研究所 王迎 王建祥;急性髓系白血病未解難題仍很多[N];健康報(bào);2013年

2 記者 馮衛(wèi)東;加找到急性髓系白血病復(fù)發(fā)根源[N];科技日?qǐng)?bào);2014年

3 通訊員 章巍 記者 程守勤;漢黃芩苷或可治療急性髓系白血病[N];健康報(bào);2013年

相關(guān)博士學(xué)位論文 前10條

1 丁超;核心結(jié)合因子相關(guān)急性髓系白血病的細(xì)胞和分子遺傳學(xué)異常[D];蘇州大學(xué);2015年

2 尹甲偉;BCL11A在中國(guó)急性髓系白血病病人中的表達(dá)水平及其調(diào)控機(jī)制研究[D];蘇州大學(xué);2015年

3 王凌波;聚二磷酸腺苷核糖聚合酶1在急性髓系白血病中的作用及機(jī)制研究[D];山東大學(xué);2016年

4 許華;SIRT2在急性髓系白血病多藥耐藥中的作用研究[D];北京協(xié)和醫(yī)學(xué)院;2016年

5 余國(guó)攀;AML1/ETO陽(yáng)性急性髓系白血病的分子生物學(xué)特征與分層診斷體系的建立[D];南方醫(yī)科大學(xué);2016年

6 陳曉平;地塞米松抑制t(8;21)急性髓系白血病細(xì)胞增殖的研究[D];中國(guó)人民解放軍醫(yī)學(xué)院;2016年

7 王利軍;Chidamide對(duì)急性髓系白血病作用及相關(guān)機(jī)制的研究[D];中國(guó)人民解放軍醫(yī)學(xué)院;2016年

8 胡超;miR-550-1在急性髓系白血病中的抑癌作用及其機(jī)制研究[D];浙江大學(xué);2016年

9 肖敏;急性髓系白血病的分子診斷研究[D];華中科技大學(xué);2011年

10 王迪;急性髓系白血病基因突變的檢測(cè)[D];華中科技大學(xué);2012年

相關(guān)碩士學(xué)位論文 前10條

1 郝其姍;1.t(1;9)(p22;q34)形成DEK/NUP214的急性髓系白血病一例報(bào)告并文獻(xiàn)復(fù)習(xí) 2.急性髓系白血病IGF2BPs和Nek2的表達(dá)及預(yù)后研究[D];北京協(xié)和醫(yī)學(xué)院;2015年

2 矯麗麗;IA方案在急性髓系白血病療效及副反應(yīng)的臨床研究[D];泰山醫(yī)學(xué)院;2014年

3 耿麗;MTT法體外藥敏試驗(yàn)在優(yōu)化急性髓系白血病治療方案中的應(yīng)用[D];河北醫(yī)科大學(xué);2015年

4 王琰;CD_(56)在急性髓系白血病的表達(dá)及意義[D];青海大學(xué);2016年

5 馬瑩瑩;IDH1基因突變對(duì)急性髓系白血病影響的Meta分析[D];山西醫(yī)科大學(xué);2016年

6 李玲;CD56在急性髓系白血病患者的表達(dá)及預(yù)后分析[D];山西醫(yī)科大學(xué);2016年

7 劉正彪;親緣間單倍體非體外去T細(xì)胞外周血造血干細(xì)胞移植治療急性髓系白血病療效及預(yù)后分析[D];新疆醫(yī)科大學(xué);2016年

8 鄭玉婷;急性髓系白血病患者骨髓中WT1基因的表達(dá)及其對(duì)預(yù)后的影響和意義[D];安徽醫(yī)科大學(xué);2016年

9 王瑞芳;急性髓系白血病的療效及其影響因素分析[D];吉林大學(xué);2016年

10 趙淑一;中劑量阿糖胞苷鞏固治療急性髓系白血病療效分析[D];新疆醫(yī)科大學(xué);2016年

本文編號(hào)：1984854